Best Bisphosphonate Threshold for 10-Year Vertebral and Non-vertebral Fracture Mitigation

Area of Science:

• Osteoporosis research
• Pharmacotherapeutics
• Bone mineral density

Background:

• Global T-score standards for osteoporosis treatment may not be universally applicable.
• Ethnicity and regional variations can influence bone mineral density (BMD) thresholds.

Purpose of the Study:

• To determine ideal bone mineral density (BMD) thresholds for initiating bisphosphonate therapy in a Jordanian cohort.
• To establish a national protocol for bisphosphonate prescription tailored to the local population.

Main Methods:

• Retrospective analysis of 328 adult patients suspected of osteoporosis.
• Utilized Fracture Risk Assessment Tool (FRAX) and logistic regression, ROC, and sensitivity analyses.
• Evaluated sensitivity, specificity, and accuracy of prognosticators for osteoporosis.

Main Results:

• Identified an optimal BMD threshold of 0.775 g/cm² for bisphosphonate initiation in Jordanian patients.
• This threshold showed significant potential in reducing hip osteoporosis risk over 10 years (sensitivity 78.6%, specificity 88.46%).
• The findings suggest a need for localized BMD guidelines over global standards.

Conclusions:

• Regional or national specific BMD thresholds are preferable to global T-score standards for bisphosphonate initiation.
• This approach accounts for ethnic differences and optimizes osteoporosis management.
• Developing a tailored national protocol enhances the effectiveness of bisphosphonate pharmacotherapeutics.